Who makes Placebo + background APT + SMT?

Placebo + background APT + SMT is developed by North Texas Veterans Healthcare System.

What development phase is Placebo + background APT + SMT in?

Placebo + background APT + SMT is FDA-approved (marketed).

Last reviewed 2026-05-15 · How we verify

Placebo + background APT + SMT

North Texas Veterans Healthcare System · FDA-approved active Small molecule

This is a placebo control arm combined with background standard care (APT and SMT) used in clinical trials to establish baseline efficacy and safety.

At a glance

Generic name	Placebo + background APT + SMT
Sponsor	North Texas Veterans Healthcare System
Modality	Small molecule
Phase	FDA-approved

Mechanism of action

This represents a control group in a clinical trial rather than an active pharmaceutical agent. APT (antiplatelet therapy) and SMT (standard medical therapy) form the background treatment, while placebo serves as the inert comparator to measure the true effect of an investigational intervention. The combination allows researchers to isolate the benefit of the experimental treatment above standard care.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial) (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Placebo + background APT + SMT CI brief — competitive landscape report
Placebo + background APT + SMT updates RSS · CI watch RSS
North Texas Veterans Healthcare System portfolio CI